Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Clinical Study of PAL-222 Targeting Patients With Refractory Skin Ulcer

NCT07016438 is registered in ClinicalTrials.gov with PharmaBio Corporation as lead sponsor.

NCT NCT07016438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07016438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Clinical Study of PAL-222 Targeting Patients With Refractory Skin Ulcer
Lead sponsor
PharmaBio Corporation
Phase
Not applicable
Overall status
Recruiting
Start date
April 15, 2025
Completion date
December 31, 2025
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory skin ulcer